Alkermes (8AK) Price & Analysis
8AK Stock Chart & Stats
- Day’s Range
- EUR 40.49 - EUR 40.70
- 52-Week Range
- EUR 23.20 - EUR 48.28
- Previous Close
- EUR 40.77
- Volume
- 0
- Average Volume (3M)
- 13
- Market Cap
- EUR 6.79B
- Enterprise Value
- EUR 10.01B
- Total Cash (Recent Filing)
- EUR 656.58M
- Total Debt (Recent Filing)
- EUR 1.57B
- Price to Earnings (P/E)
- 112.5
- Beta
- 0.71
- Next Earnings
- Nov 03, 2026
- EPS Estimate
- -0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Proprietary Product Growth
Broad growth across the proprietary portfolio demonstrates meaningful commercial traction in psychiatry, addiction and sleep medicine. A larger branded revenue base can support continued investment, improve operating leverage over time, and reduce reliance on any single product or partnered revenue stream.
Advancing Orexin Pipeline
Positive early clinical evidence for ALKS 7290 expands Alkermes’ potential beyond its current commercial portfolio and supports a differentiated orexin strategy. Alongside advancing narcolepsy and idiopathic hypersomnia programs, the pipeline could create additional durable growth options if later-stage results confirm efficacy.
Positive Cash Generation
Positive operating and free cash flow show that the company is converting its commercial platform into internally generated funding. This supports ongoing research, commercialization and debt service while providing greater flexibility than a business dependent primarily on external financing.
Bears Say
Higher Leverage
The sharp increase in leverage raises fixed financial obligations and reduces flexibility if product growth or cash generation weakens. Although equity remains sizable, higher debt can constrain capital allocation and leave fewer resources available for pipeline investment or unexpected operating pressure.
Profitability Compression
The steep margin decline weakens confidence in the durability of current earnings, even as revenue has returned to modest growth. Lower profitability reduces the cash available for reinvestment and makes the company more sensitive to higher commercialization, development and financing costs.
LYBALVI Gross-to-net Pressure
Rising gross-to-net deductions mean prescription growth may translate into less net revenue and weaker product economics. While broader access can support volume, sustained pricing and reimbursement pressure could limit margin expansion and reduce the contribution of LYBALVI to long-term earnings.
Alkermes News
8AK FAQ
What was Alkermes’s price range in the past 12 months?
What is Alkermes’s market cap?
When is Alkermes’s upcoming earnings report date?
How were Alkermes’s earnings last quarter?
Is Alkermes overvalued?
Does Alkermes pay dividends?
What is Alkermes’s EPS estimate?
How many shares outstanding does Alkermes have?
What happened to Alkermes’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alkermes?
What is the TipRanks Smart Score and how is it calculated?
Alkermes Stock Smart Score
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Blair Jackson
- Employees
- 2,050
- Website
- www.alkermes.com
- Address
- Connaught House, Dublin, DU, D04 C5Y6, IE
Alkermes (8AK) Earnings & Revenues
8AK Company Deck
8AK Earnings Call
Earnings Call SentimentPositive
The call conveyed strong commercial momentum and meaningful clinical progress, particularly across the orexin franchise and the successful integration of Avadel/LUMRYZ. Key revenue and access wins (proprietary sales +34% YoY, LYBALVI access >80%, LUMRYZ patient growth +25% YoY) and robust pipeline readouts (alixorexton LTE durability, Positive LUMRYZ Phase 3, multiple orexin programs advancing) underpin optimism. Offsetting items include margin pressure from expanding gross-to-net (LYBALVI), a substantial increase in R&D and SG&A tied to pipeline advancement and acquisition integration, a contingent consideration charge that pushes the GAAP loss guidance negative, and competitive/pricing uncertainty from other orexin entrants. Overall, the positive commercial and clinical developments outweigh the cost and near-term margin headwinds.
View all DE:8AK earnings summaries8AK Net sales Breakdown
- 89.69% U.S.
- 10.24% Rest of world
- 0.07% Ireland
8AK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 11 | 0 | 1 |